Cargando…

EE43 Budget Impact Analysis of Favipiravir (AVIGAN®) for the Treatment of Patients with Confirmed Infection with SARS-COV2 in Mexico

Detalles Bibliográficos
Autores principales:	Paladio Hernández, JÁ, Godina-Ortiz, BA, Lara-Terrazas, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232720/ http://dx.doi.org/10.1016/j.jval.2022.04.295

Ejemplares similares

A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful
por: Hirouchi, Takatomo, et al.
Publicado: (2021)

Electrical Power Budget for FCC-ee
por: Aull, S., et al.
Publicado: (2016)

Benefits of Minimizing the Vertex Detector Material Budget at the FCC-ee
por: Freitag, Leila
Publicado: (2023)

Favipiravir use for SARS CoV-2 infection
por: Boretti, Alberto
Publicado: (2020)

EE99 Economic Burden of COVID-19 in Mexico
por: Frias Gasga, AE, et al.
Publicado: (2022)

EE527 Cost-Effectiveness and Budget Impact Analysis of Remdesivir for the Treatment of COVID-19 in Greece
por: Athanasakis, K, et al.
Publicado: (2022)

Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir
por: Peng, Qi, et al.
Publicado: (2021)

Model of the RNA Polymerase Complex of the SARS-CoV-2 Virus with Favipiravir
por: Polyakov, I. V., et al.
Publicado: (2021)

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
por: Solaymani-Dodaran, Masoud, et al.
Publicado: (2021)

Guerra de EE.UU.Contra México post Factum/
por: Instituto de Latinoamerica Academia de Ciencias de Rusia

Measurement of the cross-section for the process $ee \to ee\gamma^{*}\gamma^{*} \to eeX$ at $\sqrt{S_{ee}}$ = 189 GeV
por: Przybycien, M B
Publicado: (2000)

Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase
por: Shannon, A., et al.
Publicado: (2020)

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2021)

Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?
por: Zhao, Lei, et al.
Publicado: (2021)

Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
por: Negru, Paul Andrei, et al.
Publicado: (2022)

Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
por: Hashemian, Seyed MohammadReza, et al.
Publicado: (2022)

ICU admission and favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Measurement of the Cross-Section for the Process ee-ee gamma*gamma*-eeX at sqrt(s_ee) = 189 GeV
por: CERN. Geneva
Publicado: (1999)

Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19)
por: McCullough, Peter A.
Publicado: (2020)

Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP
por: Naydenova, Katerina, et al.
Publicado: (2021)

Favipiravir: Lack of efficacy during the treatment with SARS-CoV-2 pneumonia: case report
Publicado: (2022)

Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico
por: Sada, Mitsuru, et al.
Publicado: (2020)

Measurement of the cross-section for the process ee --> ee gamma[sup *] gamma[sup *] --> eeX at sqrt(s[sub ee]) = 189--202 GeV
por: Przybycien, M B
Publicado: (2001)

The mechanism of resistance to favipiravir in influenza
por: Goldhill, Daniel H., et al.
Publicado: (2018)

Favipiravir in Therapy of Viral Infections
por: Łagocka, Ryta, et al.
Publicado: (2021)

Favipiravir: Hyperuricaemia: case report
Publicado: (2021)

FCC-ee
por: Janot, Patrick
Publicado: (2018)

Análisis comparativo del dictamen en México y en EE.UU.
por: Buces Beaumont, Luis Manuel
Publicado: (1997)

Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition
por: Takahashi, Hidenori, et al.
Publicado: (2020)

Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort
por: Suzuki, Masahiro, et al.
Publicado: (2021)

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates
por: Marlin, Romain, et al.
Publicado: (2022)

Top-up injection for FCC-ee
por: Aiba, Masamitsu, et al.
Publicado: (2015)

Tratado de agricultura
por: Paladio, Rutilio Tauro Emiliano s. IV
Publicado: (1990)

Budget impact analysis of multiple varicella vaccination strategies: a Mexico perspective
por: Graham, Jonathan, et al.
Publicado: (2019)

Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series
por: Fu, Dian, et al.
Publicado: (2020)

Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
por: Eloy, Philippine, et al.
Publicado: (2021)

Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey
por: ERDEM, Hüseyin Aytaç, et al.
Publicado: (2021)

Favipiravir tautomerism: a theoretical insight
por: Antonov, Liudmil
Publicado: (2020)

Role of favipiravir in the treatment of COVID-19
por: Joshi, Shashank, et al.
Publicado: (2021)

Novel Polymorph of Favipiravir—An Antiviral Medication
por: Goloveshkin, Alexander S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4s4sb7g41s2kb7k6iinkjudsl2